[{"orgOrder":0,"company":"Expert Systems","sponsor":"Lomond Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lonitoclax","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Expert Systems","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Expert Systems \/ Lomond Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Expert Systems \/ Lomond Therapeutics"},{"orgOrder":0,"company":"Expert Systems","sponsor":"Eilean Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Expert Systems","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Expert Systems \/ Eilean Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Expert Systems \/ Eilean Therapeutics"},{"orgOrder":0,"company":"Expert Systems","sponsor":"Polku Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Expert Systems","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Expert Systems \/ Polku Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Expert Systems \/ Polku Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Expert Systems

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Lonitoclax has a best-in-class potency and selectivity against BCL-2. Currently, it is being evaluated for the treatment of chronic lymphocytic leukemia.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 17, 2024

                          Lead Product(s) : Lonitoclax

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Lomond Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The partnership aims to support the clinical advancement of Eilean's lead PTPN2 inhibitor, which is being evaluated in the preclinical trial studies for the treatment of patients related to neoplasms.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          December 03, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Eilean Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The collaboration of Polku Therapeutics with Expert Systems to focus on the early-stage drug discovery for the treatment of neurodegenerative disorders.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          September 18, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Discovery Platform

                          Sponsor : Polku Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank